GNCA - Earnings call transcript Q4 2019 | Genocea Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen. And welcome to the Genocea Fourth Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded.

to conference like host, to now Mr. would turn over the your I Ferry. Dan Go ahead, sir.

Dan Ferry

and everyone. we good issued operator, tab. available you, Thank morning, the under release today. release Investors outlines at discuss genocea.com, a Earlier that the to topics plan This is press we today,

During call prepared for Genocea's, the the to and company's will Officer, Chip; Chief a and the Diantha Clark, we remarks, financial Flechtner, corporate Davis, up will brief Duvall, questions. Scientific available CEO, Q&A, today, Diantha; Tom then and Chip Chief Jessica review results. Financial the open After answer update. call will your be President provide And Officer; Medical Officer, Genocea's, Chief the will

everyone All call are business may this XXXX. Actual forward-looking statements provided could Litigation made Before Genocea. beyond we under that and or future the as begin, statements impact the Reform many defined forecasts relating performance, Private future Genocea's to of be the I Harbor Safe conference expected prospects future or forward-looking statements control the plans differ intended protection events Securities results remind during due include such would Act subject outcomes from to Act. to the factors Reform those by of to materially of like to

Risk reports directed Commission. and the result and other as expressly XX-K information, Genocea to the its annual filed to set future Participants disclaims report with Securities any Genocea's duty of XXXX new a are Form or updates statements, whether forth to periodic Exchange forward-looking on provide events in otherwise. Factors

the pass to pleasure over call my now to is Chip. It

Chip Clark

and I Genocea of for scientific all you in clinical first path-breaking neoantigen review important thank made our XXXX. to the profiling on and fourth work And joining us selection. progress Dan. today. quarter want Thanks,

conventional calling again We to work antigen want selection are our which through once we about neoantigens reshaping inhibigen. the think I we're inhibitory wisdom. work talk unique on now inhibigen Specifically

neoantigens. words, GEN-XXX anti-tumor by the ours neoantigens immunogenicity a trigger showed faithfully other In our bioassay system patient's the responses. can through T conclusively showed right expressed data the are such cell have presented only to and tumor, as that and we been systematically the can first We immune which that those right identify

GEN-XXX’s But wrong not find our would if the ability if we compelling a vaccines find immune what from antigen. as there's are therapies. ATLAS’s Surely, them truly stem these antigens? just a responses not for right thing and want on to relying ensure such we and to What cell

showed SITC showed responses. cell certain to we antigens is that by dampening immune that can responses We immunotherapy November. what This the exactly T drive in anti-tumor counter at cancer goals run

in with stringent reversed recap, the To same otherwise in responses BXXFXX promotes that that compellingly actually we an inhibigens showed mouse tumor anti-tumor more Even vaccine inhibigens protected model. in model. melanoma vaccination growth

Think immune to implications, cancer demonstrates including inhibigens. us a excluding about and antigens the to immunotherapy responses this that also the maximizing both the right requires

therapy responses GEN-XXX. are two and the GEN-XXX, other cell from in to we've two expect immune demonstrated things words unparalleled There reasons for reasons our good in

actions this investigate to expect implications We their year. continue to more inhibigens on and share and

by participants. trial We completed of patient this we our disease with SITC also study neoantigen vaccine. our advance the was cohort. in continue observed GEN-XXX monotherapy well Part At we patient progression reported Phase dosing to vaccinated in GEN-XXX that A X/Xa no tolerated

also should and relevant. selection the of not responses immunogenicity the cargo, for its importance generated just ATLAS of note the antigen of responses GEN-XXX neoantigens high, essentially to we A XX% Part vaccine immune because that confirmed results were ATLAS The of immune all but

responses ATLAS can to succumbed strong antigens. to the GEN-XXX ensures seeming year's this tumor immune to pointlessness flu antigens. attest but immune of flu of still responses to Those relevant be vaccine received us should that wrong who the the the

That to position responses shrinkage first meaningful GEN-XXX why potentially to on to tumor believe be neoantigenvaccine we the therapy. immune checkpoint is demonstrate inhibitor strong these top that continue of immune

study the care from immune which neck head cancers. designed is with and come B combination standard GEN-XXX in including of vaccine with to would in This the non-small and cell checkpoint evaluate patients disease, Part of inhibitors advanced lung

We have QX, results anticipate we begun dosing clinical and reporting QX. in preliminary

to GEN-XXXrests program, therapy T next the on I for several our cell want speak converging case We think to new GEN-XXX. trends. exciting

but cell hope adaptive therapy new unselected can is solidifying with or solid the refractory First specific, tumors. lymphocytes tumor-infiltrating bulk using confidence provide that neoantigen to TILs patients

NCI reported specific for the improve Institute cells National at Cancer have pioneers neoantigen can sorting T TILs as or outcomes. Second, patient

the at the in the have recently those periphery team the tumor. can cell the as in mirror very T confirmed Third, NCI cohort

points and that right a for and inhibigens. get clinic. it T that product from the sorted argue into for really to is GEN-XXX we're These are neoantigens uses cells course periphery of the together This that excited the exclude

a in the half intend efficient manufacturing We new anticipate in developing progress process file first investigational for GEN-XXX. have quarter an application to XXXX. next preliminary drug significant and results We clinical productive of and made reporting

of Medical President, of Affairs appointed effective Development our Medical Chief One Yesterday Product we more and and Directors Officer to of Board piece news. Dr. Schwab, February XXth, Exelixis Gisela XXXX.

terrific a make to going she's addition. think I

to and and was preclinical continue look support our data it pivotal clinical platform positive we of We this to a in both in regulatory demonstrate our of proprietary milestones. and XXXX, a XXXX range continuing through forward pipeline. momentum For data as year

financials the quarter going our call the now to to opening this summarize over before I'm Diantha, to pass call Diantha? to questions. from

Diantha Duvall

cash of quarter with And ended million cash Chip. Thanks, good morning, We everyone. and equivalents. the $XX.X

Our as million the XX, in period to $X.X $X.X quarter same follows, XXXX compared December XXXX. operating million were the are expenses for ended R&D results for

to $X.X compared million to period loss $X XXXX. XXXX. G&A in in expenses same million net period same our compared income million for for were $X.X was the of million net $X.X the And

quarter the XXXX. resources into existing support also reaffirm We that first cash of our to be sufficient operations will our

for that, open With now the up call let's questions. Operator?

Operator

Pantginis Joe Wainwright. question Your comes Instructions] [Operator first from H.C. from

Joe Pantginis

I upside with downside question. the in curious, antigen various Guys, both lot events. the taking was surely the just space a new saw and XXXX to for of volatility Thanks the

broader just when maybe - your was you discussions your [ph] the other CITI and as scientists they've describe at So you Jess for curious Can I sort been thesis? XXXX the data in-depth the and ‘XX. and how Tom, of then with immunotherapy, these inhibigen and initial data more KOLs physicians macro in inhibigen presented on and reacting in to more side field to

Chip Clark

Chip kick the for to Thanks, This question. Joe ask the I'll is off. Tom comments

Tom Davis

initially not was it some a inhibigens. the potentially system to element critical a is discussing novel there skepticism XX the Well over finding, identified. fairly of progression it's XX Clearly truly been - been since that I last yet dramatic think when a immune we had months a the were

very effectively been also that vaccines some responses, consequence the preventing inhibigens in disease. pointed out play as appear well very over have to were able the both last mouse and a show including But encouraging in to importantly role However, Joe, active the able evidence we that challenging more immune in recurrence as from clinic a year we've growth. preventing more inhibigens to you present consistent role working a data tumor in model, as as

it. might This in the to has from where actively pursuing But we our to been only therapeutics a important mechanism exclude ones better of where what the we are probably order as situation and our our a step very assuring obviously inhibigens be story such we're very identify and the them immune therapy. to can in taking success are can what understand current consistent control do

Joe Pantginis

data? like more been feedback to the any So your have about in colleagues the how space and reacting adjusting

Chip Clark

is community I a make piece ASCO. XX came So Joe, from scientific becoming of think other top Chip abstract a couple this at clinical comments. of I of important and I’ll and the from the sort feedback mean,

I needle know immuno-oncology we reflection think at a that's and clinically moving think ASCO that sort scientifically. you clear the of that were I

just as continue as no of that their address for obviously one else how peers they to our immunotherapies. identify I can And as think much might intend inhibigens, don't those to can. much have push advantage because the said for answer we we really an Tom

Joe Pantginis

Got color appreciate guys. I it. the added

Chip Clark

Joe. Thank,

Operator

Your Graybosch question Daina Leerink. from next from comes SVB

Daina Graybosch

then maybe detailed. more starting and getting top more Chip,

clinical You it? and give if bit any QX conference bit the And you us that of patients in a delay? a mentioned can next a may - that there QX. which Is on that we little many little guidance would driving results or how what's be see is delay, and at of

Chip Clark

Thanks, Daina. That is not a delay.

when when and think to just sort And the reflection of robust have speak do sure I set we where. data results. present Tom we to the a of wanting can a make it's

Tom Davis

sure be to a right has complicated So results. and the been the half data now for we second the activated we people It of our going have year perspective. last and study is want accrual we adequate amounts very to well from interpret study

can we're the from specific provided the adequate pointing this meaning tell range, year, any have in you QX. at this most believe we middle not likely patients that we'll So to of QX, late we but time, as

Daina Graybosch

That's that, more preclinical data of expect should in And we or publications great. Thank you. ahead any conferences?

Chip Clark

to strive our data at know medical rather. conferences you centers present as Absolutely major

things abstracts And present, been and so specific be providing but like accepted conferences that, not such at be until we're any I am to have guidance. going we hopeful will that

Daina Graybosch

vaccine? if when for cell think they doing And with slight cells patients cell into cell do inhibigens, of love T neoantigen and inhibigen, platforms stimulate make Would that. proliferate, - as let's something similar the select taking difference various cells the blood T - to are or if those the competitors better [ph] fine. you to are that an it the a put and That’s therapy and understand they wouldn't as you Okay. go just as their question on vivo then a much using using so relevant and say - product specific? therapy, back and I are then inhibigens wouldn't and those TILs I'd T peripheral

Chip Clark

question. Jess tackle Thanks, Daina. I'll that have

Jessica Flechtner

Thanks, Daina.

and if in influence do we products. non-specific think these the other approaches cells today the proliferate that stimulation T very product to exert cells the these or TIL neighbors, therapy cell relevant. T in their the TIL important, T These blood. important are grow approaches peripheral question cell of their peripheral over of using and – is many are as they about both to from What pool not they response that product I can these that the your more know is from in they

you well. [ph] also TIL that neoantigens be. relevant to cells antigen, products is know, these you viral cells not totally of mix and tumor of ours are products, irrelevant as transferred intended They T the as I'd T get are that pure specific specific specific remind majority inhibigen

enriched targets cells been then cell new antigen new antigen periphery they benefited the in the growing inhibigens right And T these we putting ATLAS so the and by a and more with back patients that specific a way have believe for the before. avoiding T opportunity the we specific that haven't selecting benefit to pure pool, and from really

Daina Graybosch

Thank Great. you.

Chip Clark

Diana. Thanks,

Operator

from Your Ben next Burnett from question Stifel. comes

Ben Burnett

Great. Thanks so much.

Just quick two questions.

announced to long it study. how has can vaccine? Part You in B patient that been now dosed that you I of guess the on GEN-XXX comment a took manufacture patient’s

Chip Clark

Yeah, Ben.

So than Part what we a favorably needle overall have a to time reflective, I of of space Part needle that similar the that times weeks, to stage broadly to that development. the was the time study little there for to possibly think showed B at which clinical little needle our in in compared Remember XX is better think needle a A. we needle bit reported our bit I others shown needle under the

- we settings not for but And as faster the make just currently expanded that products designed, confidence make in available for more who so patients. that more the that clinical to we can potentially assuming eligible for scale a be to potential able trial gives are future us GEN-XXX product

Ben Burnett

you what you neoantigen you that. separately, I where more different Thank question this began clinical you a guess test T of there a maybe guess GEN-XXX. patient I trials include this can once this cells in year? just then Great. is And Okay. one to then number on And population product? for limit

Chip Clark

to in speak speak to number the patient divide have initial So Tom study. question population Jess the product the to and clinical I'll I'm of up, target going then in the that neoantigens I'll

So Jess?

Jessica Flechtner

Right.

in product. we ATLAS a the for limit find defining we we're XX of we limit is that that to have products. process theoretically currently will we for put our the is set find. the today intend with just and that - number continue going But that develop these which and will is put we number everything that under identify amplifying we T upper So put the process neoantigens cells for mostly to no in The there of neoantigens we neo in to upper

Chip Clark

Tom?

Tom Davis

what an have high GEN-XXX treatments level want as that for types target immune antigens [indiscernible] is that of of course, to for just ideal tumor patients, in new these tumors would also but responses. take Jess of one So a advantage describing,

focus our companies lung, neck, to do So and head plenty tumors where renal, other for been along has which of room have response date like rates urothelial lines the there's improvement. and of

as with a IND an lot preparation the we great However refine out there. there protocol for process interesting in are filing it of has and other ideas the

we haven't list we'll really in after, have treatment this going ones So challenging what there that potential of think order for in a tumors to is. I final we're some do but test

Ben Burnett

Okay, great. Thanks for that color.

Chip Clark

Ben. Thanks,

Operator

Gil and from [Operator Blum question from Instructions] Your Company. Needham next comes

Gil Blum

question. Hi, Thanks are you taking my today? everyone. How doing for

is naturally ratio, there to if to have you begin phenomenon. therapy? inhibigen the be a occurring - unresponsive poor that this a with would chance CPI much a considering to to or back inhibigen any pretty going immunogen you immunogenic ratio other So there Is is

Chip Clark

have I’ll Gill. to take Thanks, that Jess question.

Jessica Flechtner

That profiles, If is been subjects of we checkpoint finding. have of inhibigens exactly that each treated in we number number we those and retrospective treatment. of I prior that the who when interpret to we done have we question find with correctly, studies what have their humans of your and antigens new the find are

is some that currently inhibigen respond shown very we data they We study definitively are additional think in as more in is as have whether collecting trial, and research well relative to it to to that observation checkpoint interesting prospective subsequently proportion predict clinical blockade. this the We of this neoantigens to will our answer appear a question.

Gil Blum

excluding patients consider studies? you own such Would in your clinical

Chip Clark

to part. Tom tackle that I have

Tom Davis

early Of course, to development and early I in patients. think start very it's too selecting

the confirm term that may do of about perhaps tell select have therapy, system that will of the therapy to think the type the just lot not picture you us each work And possibility patient. in respond not those described. identify that long a ATLAS finding individual can we type, Jess that we a But First able strong certain the to to who might to there's from be immune I patient. ATLAS us a that but allow get

excited we're decisions justify here we're right So creating the about clinical this data to the and will be used But that. potential now down - in line.

Gil Blum

for hope you season my All right. added flu over taking the soon. I Thank will for and questions color the and be

Chip Clark

with are that, Gill. you you. Thank We on

Operator

At comment. this the like would back time it ahead I to to Clark. go Please turn speakers for further Mr. any

Chip Clark

thanks speak again Thank for joining And today. again you, us operator. you everyone to We'll soon.

Operator

Ladies and wonderful have and today's for a participating concludes you conference. gentlemen, Thank this day.

now disconnect. may You

Genocea Biosciences (GNCAQ) 13 Feb 202019 Q4 Earnings call transcript